Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3

British Journal of Pharmacology

Volumn 166, Issue 3, 2012, Pages 912-923

  Nedjai, Belinda ^a   Li, Hubert ^b   Stroke, Ilana L ^c,e   Wise, Emma L ^a   Webb, Maria L ^c,e   Merritt, J Robert ^c,f   Henderson, Ian ^c,g   Klon, Anthony E ^c,h   Cole, Andrew G ^c   Horuk, Richard ^d   Vaidehi, Nagarajan ^b   Pease, James E ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c PHARMACOPEIA INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e LLC   (United States)

^f KEAN UNIVERSITY   (United States)

^g LIGAND PHARMACEUTICALS INC   (United States)

^h Ansaris   (United States)

Author keywords

Chemokine; chemokine receptors; CXCL10; CXCL11; CXCR3; molecular modelling; small molecule agonist

Indexed keywords

CHEMOKINE RECEPTOR AGONIST; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR3 AGONIST; CXCL11 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; PARTIAL AGONIST; UNCLASSIFIED DRUG;

ALLOSTERISM; AMINO ACID SEQUENCE; ANTIGEN RECOGNITION; ARTICLE; BINDING SITE; CELL MIGRATION; CHEMOTAXIS; CRYSTAL STRUCTURE; DRUG RECEPTOR BINDING; FLOW CYTOMETRY; GENE CONSTRUCT; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STATIC ELECTRICITY; T LYMPHOCYTE;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ANIMALS; CELL CULTURE TECHNIQUES; CELL LINE; CHEMOKINE CXCL10; CHEMOKINE CXCL11; CHEMOTAXIS; CYCLIC AMP; DNA, COMPLEMENTARY; FLOW CYTOMETRY; HUMANS; LIGANDS; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PRECURSOR CELLS, B-LYMPHOID; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTORS, CXCR3; SMALL MOLECULE LIBRARIES; TRANSFECTION;

EID: 84860866415     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01660.x     Document Type: Article

References (44)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Anghelescu AV, DeLisle RK, Lowrie JF, Klon AE, Xie X, Diller DJ, (2008). Technique for generating three-dimensional alignments of multiple ligands from one-dimensional alignments. J Chem Inf Model 48: 1041-1054.
3. Booth V, Keizer DW, Kamphuis MB, Clark-Lewis I, Sykes BD, (2002). The CXCR3 binding chemokine IP-10/CXCL10: structure and receptor interactions. Biochemistry 41: 10418-10425.
4. Charo IF, Ransohoff RM, (2006). The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354: 610-621.
5. Clark-Lewis I, Dewald B, Loetscher M, Moser B, Baggiolini M, (1994). Structural requirements for interleukin-8 function identified by design of analogs and CXC chemokine hybrids. J Biol Chem 269: 16075-16081.
6. Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP, et al,. (1998). Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 187: 2009-2021.
7. Colvin RA, Campanella GS, Sun J, Luster AD, (2004). Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J Biol Chem 279: 30219-30227.
8. Colvin RA, Campanella GS, Manice LA, Luster AD, (2006). CXCR3 requires tyrosine sulfation for ligand binding and a second extracellular loop arginine residue for ligand-induced chemotaxis. Mol Cell Biol 26: 5838-5849.
9. Cox MA, Jenh CH, Gonsiorek W, Fine J, Narula SK, Zavodny PJ, et al,. (2001). Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states. Mol Pharmacol 59: 707-715.
10. Crump MP, Gong JH, Loetscher P, Rajarathnam K, Amara A, Arenzana-Seisdedos F, et al,. (1997). Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J 16: 6996-7077.
11. Dagan-Berger M, Feniger-Barish R, Avniel S, Wald H, Galun E, Grabovsky V, et al,. (2006). Role of CXCR3 carboxyl terminus and third intracellular loop in receptor-mediated migration, adhesion and internalization in response to CXCL11. Blood 107: 3821-3831.
12. Damon I, Murphy PM, Moss B, (1998). Broad spectrum chemokine antagonistic activity of a human poxvirus chemokine homolog. Proc Natl Acad Sci U S A 95: 6403-6407.
13. DeLano WL, (2002). The PyMOL Molecular Graphics System.
14. Farber JM, (1990). A macrophage mRNA selectively induced by gamma-interferon encodes a member of the platelet factor 4 family of cytokines. Proc Natl Acad Sci USA 87: 5238-5242.
15. Fiser A, Do RK, Sali A, (2000). Modeling of loops in protein structures. Protein Sci 9: 1753-1773.
16. Flohr S, Kurz M, Kostenis E, Brkovich A, Fournier A, Klabunde T, (2002). Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J Med Chem 45: 1799-1805.
17. Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB, (2003). The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 63: 1256-1272.
18. Gong J-H, Clark-Lewis I, (1995). Antagonists of monocyte chemoattractant protein 1 identified by modification of functionally critical NH2-terminal Residues. J Exp Med 181: 631-640.
19. Han W, Liu H, Xiang D, (2010). US Patent-Methods for protecting and regenerating bone marrow using CXCR3 agonists and antagonists. Vol. US 2010/0080756 A1. USA.
20. Jarnagin K, Grunberger D, Mulkins M, Wong B, Hemmerich S, Paavola C, et al,. (1999). Identification of surface residues of the monocyte chemotactic protein 1 that affect signaling through the receptor CCR2. Biochemistry 38: 16167-16177.
21. Jensen PC, Thiele S, Ulven T, Schwartz TW, Rosenkilde MM, (2008). Positive versus negative modulation of different endogenous chemokines for CC-chemokine receptor 1 by small molecule agonists through allosteric versus orthosteric binding. J Biol Chem 283: 23121-23128.
22. Kwak HB, Ha H, Kim HN, Lee JH, Kim HS, Lee S, et al,. (2008). Reciprocal cross-talk between RANKL and interferon-gamma-inducible protein 10 is responsible for bone-erosive experimental arthritis. Arthritis Rheum 58: 1332-1342.
23. Kenakin T, (2011). Functional selectivity and biased receptor signalling. J Pharmacol Exp Ther 336: 296-302.
24. Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, et al,. (1996). Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 184: 963-969.
25. Loetscher M, Loetscher P, Brass N, Meese E, Moser B, (1998). Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol 28: 3696-3705.
26. Luster AD, Ravetch JV, (1987). Biochemical characterization of a gamma-interferon-inducible cytokine (tIP-10). J Exp Med 166: 1084-1097.
27. Luttichau HR, Stine J, Boesen TP, Johnsen AH, Chantry D, Gerstoft J, et al,. (2000). A highly selective CC chemokine receptor (CCR)8 antagonist encoded by the poxvirus molluscum contagiosum. J Exp Med 191: 171-180.
28. Mantovani A, (1999). The chemokine system: redundancy for robust outputs. Immunol Today 20: 254-257.
29. Meiser A, Mueller A, Wise EL, McDonagh EM, Petit SJ, Saran N, et al,. (2008). The chemokine receptor CXCR3 is degraded following internalization and is replenished at the cell surface by de novo synthesis of receptor. J Immunol 180: 6713-6724.
30. Monteclaro FS, Charo IF, (1996). The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES/MIP-1alpha receptor, confers chemokine selectivity. Evidence for a two-step mechanism for MCP-1 receptor activation. J Biol Chem 271: 19084-19092.
31. Murphy PM, (2002). International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol Rev 54: 227-229.
32. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, et al,. (2000). International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52: 145-176.
33. O'Boyle G, Newton P, Jenkins Y, Ali S, Kirby JA, (2010). A strategy to inhibit effector T cell infiltration of allograft tissues by stimulation of the chemokine receptor CXCR3. Transplantation 90: 144.
34. Pease JE, Horuk R, (2009). Chemokine receptor antagonists: part 2. Expert Opin Ther Pat 19: 199-221.
35. Pease JE, Wang J, Ponath PD, Murphy PM, (1998). The N-terminal extracellular segments of the chemokine receptors CCR1 and CCR3 are determinants for MIP-1a and eotaxin binding, respectively, but a second domain is essential for receptor activation. J Biol Chem 273: 19972-19976.
36. Stroke IL, Cole AG, Simhadri S, Brescia MR, Desai M, Zhang JJ, et al,. (2006). Identification of CXCR3 receptor agonists in combinatorial small molecule libraries. Biochem Biophys Res Commun 349: 221-228.
37. Tsubaki T, Takegawa S, Hanamoto H, Arita N, Kamogawa J, Yamamoto H, et al,. (2005). Accumulation of plasma cells expressing CXCR3 in the synovial sublining regions of early rheumatoid arthritis in association with production of Mig/CXCL9 by synovial fibroblasts. Clin Exp Immunol 141: 363-371.
38. Vaidehi N, Floriano WB, Trabanino R, Hall SE, Freddolino P, Choi EJ, et al,. (2002). Prediction of structure and function of G protein-coupled receptors. Proc Natl Acad Sci U S A 99: 12622-12627.
39. Vaidehi N, Pease JE, Horuk R, (2009). Modeling small molecule-compound binding to G-protein-coupled receptors. Methods Enzymol 460: 263-288.
40. Wang T, Duan Y, (2009). Ligand entry and exit pathways in the beta2-adrenergic receptor. J Mol Biol 392: 1102-1115.
41. Weng Y, Siciliano SJ, Waldburger KE, Sirotina-Meisher A, Staruch MJ, Daugherty BL, et al,. (1998). Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors. J Biol Chem 273: 18288-18291.
42. Wu B, Chien EY, Mol CD, Fenalti G, Liu W, Katritch V, et al,. (2010). Structures of the CXCR4 chemokine GPCR with small molecule and cyclic peptide antagonists. Science 330: 1066-1071.
43. Xanthou G, Williams TJ, Pease JE, (2003). Molecular characterization of the chemokine receptor CXCR3: evidence for the involvement of distinct extracellular domains in a multi-step model of ligand binding and receptor activation. Eur J Immunol 33: 2927-2936.
44. Zlotnik A, Yoshie O, (2000). Chemokines: a new classification system and their role in immunity. Immunity 12: 121-127.